PharmaBlock Sciences Nanjing Inc Class A Total Liabilities
PharmaBlock Sciences Nanjing Inc Class A total liabilities. Based on the latest financial reports, PharmaBlock Sciences Nanjing Inc Class A (300725) has total liabilities worth CN¥817.65 Million CNY (≈ $119.65 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check PharmaBlock Sciences Nanjing Inc Class A (300725) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of PharmaBlock Sciences Nanjing Inc Class A (2013–2025)
Total liabilities of PharmaBlock Sciences Nanjing Inc Class A from 2013 to 2025. This chart illustrates how PharmaBlock Sciences Nanjing Inc Class A's total liabilities have evolved over time, based on quarterly financial data.
PharmaBlock Sciences Nanjing Inc Class A Competitors by Total Liabilities
The table below lists competitors of PharmaBlock Sciences Nanjing Inc Class A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SASA Polyester Sanayi AS
IS:SASA
|
Turkey | TL150.95 Billion |
|
Xiamen Kingdomway Group Co
SHE:002626
|
China | CN¥3.80 Billion |
|
Vietnam National Petroleum Group
VN:PLX
|
Vietnam | ₫77.19 Trillion |
|
Nurix Therapeutics Inc
NASDAQ:NRIX
|
USA | $150.22 Million |
|
GPS Participações e Empreendimentos S.A
SA:GGPS3
|
Brazil | R$11.73 Billion |
|
Changjiang Publishing & Media Co Ltd
SHG:600757
|
China | CN¥3.73 Billion |
|
SLC Agrícola S.A
SA:SLCE3
|
Brazil | R$13.89 Billion |
|
Photronics Inc
NASDAQ:PLAB
|
USA | $247.04 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down PharmaBlock Sciences Nanjing Inc Class A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see PharmaBlock Sciences Nanjing Inc Class A asset portfolio.
Liquidity & Leverage Metrics
PharmaBlock Sciences Nanjing Inc Class A Total Liabilities Ratios Explained
PharmaBlock Sciences Nanjing Inc Class A total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.94 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PharmaBlock Sciences Nanjing Inc Class A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PharmaBlock Sciences Nanjing Inc Class A (2013–2025)
The table below shows the annual total liabilities of PharmaBlock Sciences Nanjing Inc Class A from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.04 Billion ≈ $152.15 Million |
-46.62% |
| 2024-12-31 | CN¥1.95 Billion ≈ $285.01 Million |
-14.26% |
| 2023-12-31 | CN¥2.27 Billion ≈ $332.43 Million |
+3.05% |
| 2022-12-31 | CN¥2.20 Billion ≈ $322.60 Million |
+150.74% |
| 2021-12-31 | CN¥879.21 Million ≈ $128.66 Million |
+65.71% |
| 2020-12-31 | CN¥530.57 Million ≈ $77.64 Million |
+84.05% |
| 2019-12-31 | CN¥288.27 Million ≈ $42.18 Million |
+78.57% |
| 2018-12-31 | CN¥161.43 Million ≈ $23.62 Million |
+153.02% |
| 2017-12-31 | CN¥63.80 Million ≈ $9.34 Million |
+41.78% |
| 2016-12-31 | CN¥45.00 Million ≈ $6.58 Million |
+73.63% |
| 2015-12-31 | CN¥25.92 Million ≈ $3.79 Million |
+80.29% |
| 2014-12-31 | CN¥14.38 Million ≈ $2.10 Million |
-3.97% |
| 2013-12-31 | CN¥14.97 Million ≈ $2.19 Million |
-- |
About PharmaBlock Sciences Nanjing Inc Class A
PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial manufacturing in China and internationally. It offers medicinal chemistry-oriented SAR/SPR tool kits for molecule design; building blocks enabled libraries, including fragment-based drug discovery, and mega virtual library screening to support the di… Read more